Kazia Therapeutics (KZIA) AI Stock Analysis

• Market Cap: $4.30M
• Dividend Yield: N/A
• Average Volume (3M): 246.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: N/A
• EPS Growth: 19.58%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -6.66
• Shares Outstanding: 5,589,294
• 10 Day Avg. Volume: 65,872
• 30 Day Avg. Volume: 246,522
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.94
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3.00
• Price Target Upside: 289.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Kazia Therapeutics struggles with financial instability, characterized by declining revenues, negative equity, and insufficient cash flow. These issues are compounded by a negative valuation with no dividend yield and a bearish technical outlook, all of which significantly hinder the stock's attractiveness and growth prospects.

Positive Factors

Market Potential

Paxalisib has shown numerical overall survival benefits in studies involving glioblastoma patients, presenting an attractive opportunity due to the lack of progress in treatment options.

Research and Development

A research grant was awarded to Kazia to evaluate paxalisib as a treatment for Parkinson's disease, highlighting a novel opportunity for the company.

Strategic Initiatives

The strategic focus on initiating the Phase 3 trial for paxalisib to treat glioblastoma multiforme patients is considered attractive, reinforcing a buy recommendation.

Negative Factors

Financial Requirements

Additional capital will likely be required to continue clinical operations, which can occur in various forms.

Kazia Therapeutics Business Overview & Revenue Model

Company Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

How the Company Makes Money

Kazia Therapeutics primarily generates revenue through the development and potential commercialization of its drug candidates. The company seeks to advance its therapies through clinical trials and, upon successful results and regulatory approval, aims to license its drugs to larger pharmaceutical companies or bring them to market directly. Key revenue streams include milestone payments, royalties from licensing agreements, and potential sales revenue of approved drugs. Partnerships with research institutions and pharmaceutical companies also play a crucial role in funding and advancing their drug development programs.

Kazia Therapeutics Financial Statement Overview

Summary

Kazia Therapeutics is facing financial challenges with declining revenues, persistent losses, and negative equity. The company struggles with cash flow generation and financial stability, which could affect its ability to sustain operations without significant changes or external funding.

Income Statement

Kazia Therapeutics has shown declining revenue over the years with a significant drop in total revenue in the most recent period. The company is experiencing a negative net profit margin, indicating it is not profitable. Moreover, both EBIT and EBITDA margins are negative, highlighting operational inefficiencies and challenges in controlling costs.

Balance Sheet

The company's financial structure is concerning, with negative stockholders' equity in the latest period, indicating liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, which poses a financial risk. Moreover, the equity ratio is negative, underscoring the financial instability and leverage issues.

Cash Flow

There is a negative operating cash flow and free cash flow, indicating that the company is not generating sufficient cash from its operations. The free cash flow growth rate is negative, suggesting worsening liquidity and inability to cover expenses without external financing.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
2.31M	555.00	25.00	15.18M	1.06K
	Gross Profit
2.31M	555.00	25.00	15.18M	1.06K
	EBIT
0.00	-24.12M	-26.70M	-6.38M	-12.53M
	EBITDA
-26.77M	-22.28M	-23.51M	-5.11M	-11.11M
	Net Income Common Stockholders
-26.78M	-20.47M	-24.65M	-8.42M	-12.47M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.66M	5.24M	7.36M	27.59M	8.76M
	Total Assets
21.59M	28.09M	34.96M	58.09M	23.06M
	Total Debt
634.00K	1.80M	1.84M	0.00	0.00
	Net Debt
-1.02M	-3.44M	-5.52M	-27.59M	-8.76M
	Total Liabilities
31.60M	16.03M	16.32M	20.24M	8.94M
	Stockholders Equity
-10.02M	12.05M	18.64M	37.85M	14.13M
Cash Flow		Free Cash Flow
-9.58M	-15.16M	-22.76M	-9.11M	-8.81M
	Operating Cash Flow
-9.58M	-15.16M	-22.76M	-9.11M	-8.81M
	Investing Cash Flow
0.00	0.00	-2.36M	0.00	0.00
	Financing Cash Flow
5.99M	12.97M	3.73M	28.11M	12.14M

Kazia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.77
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZIA, the sentiment is Negative. The current price of 0.77 is below the 20-day moving average (MA) of 0.85, below the 50-day MA of 0.95, and below the 200-day MA of 3.18, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 37.08 is Neutral, neither overbought nor oversold. The STOCH value of 4.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KZIA.

Kazia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	54 Neutral	$39.62M	1.35	-58.97%	―	36.45%	―
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
BLUE	36 Underperform	$45.72M	―	-295.35%	―	184.12%	31.92%
IMUX	36 Underperform	$86.25M	―	-424.44%	―	―	51.02%
KZIA	31 Underperform	$4.30M	―	-2639.52%	―	―	19.58%
AGEN	26 Underperform	$43.03M	―	260.68%	―	-33.81%	23.02%